Identification of Modulators of HIV-1 Proviral Transcription from a Library of FDA-Approved Pharmaceuticals.
AuthorSampey, Gavin C
Pleet, Michelle L
MetadataShow full item record
AbstractHuman immunodeficiency virus 1 (HIV-1) is the most prevalent human retrovirus. Recent data show that 34 million people are living with HIV-1 worldwide. HIV-1 infections can lead to AIDS which still causes nearly 20,000 deaths annually in the USA alone. As this retrovirus leads to high morbidity and mortality conditions, more effective therapeutic regimens must be developed to treat these viral infections. A key target for intervention for which there are no current FDA-approved modulators is at the point of proviral transcription. One successful method for identifying novel therapeutics for treating infectious diseases is the repurposing of pharmaceuticals that are approved by the FDA for alternate indications. Major benefits of using FDA-approved drugs include the fact that the compounds have well established toxicity profiles, approved manufacturing processes, and immediate commercial availability to the patients. Here, we demonstrate that pharmaceuticals previously approved for other indications can be utilized to either activate or inhibit HIV-1 proviral transcription. Specifically, we found febuxostat, eltrombopag, and resveratrol to be activators of HIV-1 transcription, while mycophenolate was our lead inhibitor of HIV-1 transcription. Additionally, we observed that the infected cells of lymphoid and myeloid lineage responded differently to our lead transcriptional modulators. Finally, we demonstrated that the use of a multi-dose regimen allowed for enhanced activation with our transcriptional activators. © 2020 by the authors.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/13847
- Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
- Authors: Hayashi T, Jean M, Huang H, Simpson S, Santoso NG, Zhu J
- Issue date: 2017 Oct
- Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
- Authors: Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK
- Issue date: 2016 Jul
- HIV "shock and kill" therapy: In need of revision.
- Authors: Abner E, Jordan A
- Issue date: 2019 Jun
- A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
- Authors: Abner E, Stoszko M, Zeng L, Chen HC, Izquierdo-Bouldstridge A, Konuma T, Zorita E, Fanunza E, Zhang Q, Mahmoudi T, Zhou MM, Filion GJ, Jordan A
- Issue date: 2018 May 15
- Heme arginate potentiates latent HIV-1 reactivation while inhibiting the acute infection.
- Authors: Shankaran P, Vlkova L, Liskova J, Melkova Z
- Issue date: 2011 Dec